APTAMARKERS
THE NEXT GENERATION OF BIOMARKER DISCOVERY
High-Plex Proteomics
High-Plex proteomics works by translating information on specific protein abundance to information on specific DNA abundance. As such, High-Plex proteomics is succeeding by mimicking transcriptomics. All other existing High-Plex proteomics systems have been built from the bottom-up, by identifying probes for specific proteins one at a time and building an array of such probes.
At NeoVentures Biotechnology Europe we are the only ones to have taken a more powerful approach by working from the top-down. We have developed a platform based on the application of the same 16.8 million aptamers (Aptamarkers) to each sample. We characterize differential binding of these probes to potential biomarkers in biological fluids or tissues through next generation sequencing (NGS) analysis, and validations are performed through qPCR analysis of specific probes.
There are several advantages to our top-down approach:
- Greater depth of coverage 16.8 million probes versus several thousand with other platforms
- Ease of use, we do not build arrays, and there is no need for specialized equipment to perform Aptamarker analysis.
- High reproducibility, we are not using polyclonal antibodies.
- Capacity to characterize non-canonical in addition to canonical forms of proteins (post-translational modifications)
- Not limited by reference to human proteins
- Clear path to Dx applications
- NGS analysis included in pricing
High-Plex, High-Throughput Platform
- Protein Coverage : Full proteome of any sample
- Species Coverage: Human, Animal, Yeast, Plant
- Sample Requirement: Requires 10 µL of sample
- Technology: Next-Generation Sequencing (NGS)
- Applications: Biomarker discovery and validation, biomarkers PTM analysis
- Specificity and Scalability: System detects proportional change in biomarkers, independent of magnitude. No need to scale, 16.8M sequences applied to every sample.
- Output: Selected Aptamarker structures. Cytoscape analysis of structural relationships, working towards specific protein abundance
Aptamarkers Applications
Biomarkers in biofluids for any disease
Agnostic screening and the capacity to characterize targers of biomarkers.
Patient stratification in clinical trials
Exclusion for predisposition to side effects and Inclusion for treatment response.
Off-target toxicity prediction
Prediction of side effect response and translation from animal models
Target engagement characterization
Mapping drug binding sites and developing dynamic test for on/off rates.
Our Vision
The Aptamarker platform has the potential to change the nature of health care. Our vision is to enable personalized medicine to a degree that has not been previously imagined. Personalized health care means personalized diagnosis. We are building a platform that will learn and improve with each additional individual analysed. This will require integration of artificial intelligence and automation. The ultimate goal is to observe the frequencies of everything in blood, to compare this to individual base levels and to determine when something is going wrong immediately as a result of changes. Our platform is the first that makes a future vision like this imaginable and feasible. There is much to do, but overcoming the inevitability of a disease like AD is where we start. We are looking for investors and partners who are committed to creating sustainable improvements to existing health care systems. The basis of such a system will be one that provides individuals with the tools and capacity to manage their own health and wellness.